← Leaderboards
Michael Vitoldovich Paukshto
Fibralign Corporation
$2,031,437
Attributed
$4,062,874
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $998.2K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,062,874 · 2
By mechanism
R44$2,965,714 · 1
R01$1,097,160 · 1
Top collaborators
- David Woosuk Chang3 shared
- Stanley G Rockson3 shared
- Ngan F. Huang2 shared
Most similar at Fibralign Corporation
Same institution · by research overlap
- David Woosuk Chang$484,031
- Michael Paukshto$179,964
Others in their field
Other Emerging Leaders on “Malignant Breast Neoplasm”
- Greg Yothers · University Of Chicago$35,003,821
- Olwen Hahn · Brigham And Women'S Hospital$32,076,706
- Leonard Freedman · Leidos Biomedical Research, Inc.$21,750,066
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Leonard Freedmand · Leidos Biomedical Research, Inc.$12,635,631
- Jessica Scott · Sloan-Kettering Inst Can Research$10,553,540
Research focus
Malignant Breast NeoplasmTissuesImplantationLymph NodesSwellingTechnologyDevicesHistologicCollagenLymphedemaOutputOperative Surgical ProceduresPre-ClinicalPreclinical StudyAffectChronicChronic DiseaseHigh RiskClinical ResearchBreast Cancer SurvivorLymphaticLymphatic VesselNatural RegenerationTreatment Strategy
Grant awards (8)
Development of a Bioengineered Therapeutic Device for the Prevention of Lymphedema$540,476
R01 · FY2025 · CA
Development of a Bioengineered Therapeutic Device for the Prevention of Lymphedema$556,684
R01 · FY2024 · CA
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$682,266
R44 · FY2021 · CA · contact PI
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$32,935
R44 · FY2020 · CA · contact PI
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$252,861
R44 · FY2019 · CA · contact PI
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$1,695
R44 · FY2019 · CA · contact PI
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$998,174
R44 · FY2018 · CA · contact PI
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$997,783
R44 · FY2017 · CA · contact PI